Practice areas

Corporate & commercial; Private equity, venture capital & fund; Capital markets; M&A

Introduction

Charles Chau has 20 years of experience in advising clients on M&A, capital markets (including listings and securities placement), securities regulatory compliance, joint ventures, and other commercial transactions across Hong Kong, mainland China and the Asia-Pacific region, covering a wide variety of industry sectors including life sciences, TMT, real estate, banking and financial services, retail and manufacturing.

On the capital markets side, Chau has worked on many IPOs and securities placement transactions including: (1) the IPOs of Sinopharm Group; China CNR Corporation; China Citic Bank; Guodian Technology & Environment Group; GenScript Biotech Corporation; China Everbright Water; CSSC (Hong Kong) Shipping; Tokyo Chuo Auction; Sino-Ocean Land; China VAST Industrial Urban Development; China South City; BBI Life Sciences; China Paradise Electronics; Kingsoft Corporation; Maoye International; and Christine International Holdings; (2) the share placements of Evergrande Real Estate; GenScript Biotech Corporation; Sinopharm Group; Guangzhou R&F; Sino-Ocean Land and Zhejiang Glass; and (3) the A+H rights issue of China Citic Bank.

Chau also represented clients in the cornerstone investment of companies to be listed, involving companies such as CMGE Technology Group, Ganglong China Property Group, Ye Xing Group Holdings, Fulu Holdings and Red Star Macalline Group.

On the M&A and investment side, Chau has been advising leading Chinese financial institutions (state owned and private) on their pre-IPO and private investment public equity (PIPE) transactions. Prior to joining Jones Day in 2017, Chau acted for China CNR Corporation in its USD26 billion merger with CSR Corporation, which was the first merger of two companies listed in both Hong Kong and Shanghai. He has also represented Chinese companies on outbound acquisitions in the US and Europe.

Chau has been repeatedly ranked as a leading individual in the areas of M&A or equity capital markets by Chambers Asia-Pacific, Legal 500 Asia Pacific, and International Financial Law Review 1000.

Back to China A-List 2021